VON WILLEBRAND DISEASE (VWD), TYPE 2
Clinical trials for VON WILLEBRAND DISEASE (VWD), TYPE 2 explained in plain language.
Never miss a new study
Get alerted when new VON WILLEBRAND DISEASE (VWD), TYPE 2 trials appear
Sign up with your email to follow new studies for VON WILLEBRAND DISEASE (VWD), TYPE 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for bleeding disorder: experimental drug HMB-002 enters human trials
Disease control Recruiting nowThis study tests a new medicine, HMB-002, for people with Von Willebrand disease (types 1 and 2), a bleeding disorder. The trial has two parts: first, a single dose to check safety and how the drug works in the body; second, repeated doses to see if it helps control bleeding. Abo…
Matched conditions: VON WILLEBRAND DISEASE (VWD), TYPE 2
Phase: PHASE1, PHASE2 • Sponsor: Hemab ApS • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New drug aims to stop bleeding in rare blood disorder
Disease control Recruiting nowThis study tests a new drug called BT200 in 4-6 adults with type 2B von Willebrand disease who have low platelets and a history of bleeding. The drug is designed to slow the breakdown of a key clotting protein, which may raise platelet levels and reduce bleeding. Participants wil…
Matched conditions: VON WILLEBRAND DISEASE (VWD), TYPE 2
Phase: PHASE2 • Sponsor: Medical University of Vienna • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New study aims to map Real-World bleeding in von willebrand disease
Knowledge-focused Recruiting nowThis study is gathering information about bleeding episodes, quality of life, and treatment use in 200 people with von Willebrand disease (VWD). Participants will report their bleeding events and complete surveys over time. The data will help researchers understand the daily impa…
Matched conditions: VON WILLEBRAND DISEASE (VWD), TYPE 2
Sponsor: Hemab ApS • Aim: Knowledge-focused
Last updated May 04, 2026 16:22 UTC